NCT02656394

Amelioration of Adverse Ocular Side Effects of Glaucoma Medications in Glaucoma Patients Using Topical GL101

Amelioration of Adverse Ocular Side Effects of Glaucoma Medications in Glaucoma Patients Using Topical GL101 - Proof of Concept, Safety, and Efficacy Study

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 49 (actual)
• Sponsor: Glia, LLC · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the safety and efficacy of 0.5% GL101 topical gel administered twice daily for 28 days in ameliorating adverse ocular side effects in patients under ongoing treatment with glaucoma medications.

Detailed description

The study is to assess the safety and efficacy of a new treatment for ocular surface disease associated with the use of glaucoma medications.

Conditions

• Ocular Surface Disease

Interventions

Type	Name	Description
DRUG	GL101	Topical Gel
DRUG	Placebo	Placebo topical gel

Timeline

• Start date: 2016-01-22
• Primary completion: 2017-12-04
• Completion: 2018-12-30
• First posted: 2016-01-15
• Last updated: 2023-03-24

Locations

1 site across 1 country: United States